12 Health Care Stocks Moving In Friday's Intraday Session
Vicarious Surgical Receives NYSE Noncompliance Notice
Vicarious Surgical Receives Written Notice From The NYSE Regarding Continued Listing Standard
Express News | Vicarious Surgical Receives Continued Listing Standard Notice From the NYSE
Following the chips and AI, the USA may consider launching a national strategy for Siasun Robot&Automation.
① USA companies urge the government to launch a Siasun Robot&Automation national strategy to promote the development of the smart robot Industry and drive the development of next-generation robots in Global competition; ② The USA Association for Advanced Automation recommends that the government adopt tax incentive measures, provide federal funding, and establish a new federal robotics office to expand production capacity and promote the application of AI.
Vicarious Surgical: Pres Randy Clark Will Transition to Bd Member, Effective April 25 >RBOT
Vicarious Surgical: 'Transition Allows Us to Retain His Insights While Evolving Our Leadership Structure to Best Serve the Company's Strategic and Cap Needs' >RBOT
Express News | Vicarious Surgical Announces President Transition to Board Member Role
Musk made a statement! The most stable niche market is this?
Who can take on Potean Wealth.
Vicarious Surgical Non-GAAP EPS of -$2.43 Beats by $0.05
NVIDIA GTC - A New Era of Generalist Robotics
Vicarious Surgical's Earnings Call: Achievements and Challenges
TD Cowen Maintains Vicarious Surgical(RBOT.US) With Buy Rating, Maintains Target Price $13
BTIG Maintains Vicarious Surgical(RBOT.US) With Hold Rating
Piper Sandler Maintains Neutral on Vicarious Surgical, Lowers Price Target to $8.5
Vicarious Surgical Analyst Ratings
Piper Sandler Remains a Hold on Vicarious Surgical (RBOT)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Vicarious Surgical (RBOT), Alkermes (ALKS) and Zealand Pharma (OtherZLDPF)
Vicarious Surgical Reports 2024 Financial Results and Progress
Vicarious Surgical's Promising Progress: Buy Rating Affirmed Amid Strategic Milestones and Clinical Advancements